Daklinza

Indicated For

Chronic Hepatitis C (HCV genotype 3)

About This Medication

# Daklinza Patient Guide: How to Get Daklinza at Low or No Cost **Important Notice: Daklinza (daclatasvir) has been discontinued by the manufacturer, Bristol-Myers Squibb (BMS), and is no longer available through standard channels.** This guide provides historical information on past assistance options and current alternatives for managing chronic hepatitis C (HCV), particularly genotypes 1 and 3, for which Daklinza was approved.[1][2][5] ## About Daklinza Daklinza (daclatasvir) is an oral medication that was used to treat chronic hepatitis C virus (HCV) infections, specifically genotypes 1 and 3. It works as an NS5A replication complex inhibitor, blocking key steps in the virus's life cycle to help achieve sustained virologic response (SVR), meaning the virus is undetectable 12 weeks after treatment.[2][5][6] Approved by the FDA in 2015, it was typically taken once daily at 60 mg, in combination with sofosbuvir (Sovaldi), with or without ribavirin, for 12 or 24 weeks depending on factors like cirrhosis status or prior treatment history.[2][3][4][5] This all-oral regimen was a breakthrough for genotype 3 patients, one of the harder-to-treat types, offering high SVR rates (up to the vast majority in clinical trials like ALLY-3).[2][7] Common side effects included fatigue, headache, and nausea, but it was generally well-tolerated when used as directed.[6][8] Daklinza required a prescription and was often part of prior authorization processes by insurers due to its targeted use.[3][4] **Unfortunately, as of recent updates, this specific form and dosage of Daklinza is discontinued and no longer manufactured or available new.** Patients should consult their doctor immediately for updated treatment plans.[1] ## Who Qualifies for Assistance? Since Daklinza is discontinued, there is **no current manufacturer patient assistance program (PAP) from Bristol-Myers Squibb**. Historically, BMS offered Patient Support Connect, which provided free medication to uninsured patients or copay help for those with private insurance.[5] Eligibility typically required U.S. residency, age 18+, a valid HCV diagnosis, and proof of financial need. Today, third-party foundations like the PAN Foundation or HealthWell Foundation may offer support for HCV treatments, including copay assistance if Daklinza were available or for alternatives. Contact them directly: PAN Foundation via GoodRx listings or HealthWell for financial aid.[1] Qualification often hinges on household income, insurance status, and medical necessity confirmed by a doctor. ## Income Eligibility Breakdown No active BMS PAP exists, so specific income thresholds (e.g., Federal Poverty Level or FPL percentages) are not applicable. Past BMS programs generally targeted those below 400-500% FPL, but details varied.[5] For foundation alternatives: | Household Size | Typical Max Income (e.g., HealthWell/PAN, ~400-500% FPL)* | Notes | |---------------|-------------------------------------------------------|-------| | Individual | $60,000 - $75,000 annually | Varies by fund; proof required | | Couple | $80,000 - $100,000 annually | Household income only | | Family of 3 | $100,000 - $125,000 annually | Includes dependents | | Family of 4 | $120,000 - $150,000 annually | Excludes non-dependent income | *Estimates based on common PAP/FPL guidelines; always verify with the specific foundation as thresholds change. No Medicare patients typically qualify for free drug PAPs.[1] ## Insurance Requirements Daklinza often required prior authorization (PA) from insurers, proving medical necessity like confirmed HCV genotype 1/3, age 18+, no contraindications (e.g., severe CKD), and combination with sofosbuvir.[3][4] Medicare Part D or Medicaid might cover alternatives today, but Daklinza itself is unavailable. Uninsured patients sought foundation help; those with commercial insurance could get copay cards historically.[5] If insured, check for coverage of generic daclatasvir or newer HCV drugs like glecaprevir/pibrentasvir (Mavyret). ## Step-by-Step Application Process 1. **Confirm Availability**: Discuss with your doctor—Daklinza is discontinued. Ask about alternatives like Epclusa or generics.[1][6] 2. **Contact Foundations**: Call PAN Foundation or HealthWell (via GoodRx) for HCV copay/drug assistance. Provide diagnosis proof.[1] 3. **Gather Documents**: Typically, proof of income (tax returns, pay stubs), prescription, HCV labs/genotype confirmation, insurance denial (if applicable), and doctor's letter.[3][4] 4. **Apply Online/Phone**: Use foundation websites or hotlines. Historically for BMS: 1-800-736-0003 or online forms.[5] 5. **Submit and Follow Up**: Fax/email docs; track status. Past processing took weeks. 6. **Appeal if Needed**: If denied, resubmit with more info. ## Timeline and Delivery Historical BMS PAP processing: 2-4 weeks. Foundations vary (1-6 weeks). Once approved, meds shipped directly to your home or pharmacy free of charge.[1][5] Refills required reauthorization every 12 weeks. Today, expect similar for alternatives. ## Alternatives if Denied or Unavailable - **Newer HCV Drugs**: Sofosbuvir/velpatasvir (Epclusa), glecaprevir/pibrentasvir (Mavyret)—pan-genotypic, often 8-12 weeks, high cure rates.[6] - **Generics**: Daclatasvir generics may exist outside U.S.; check GoodRx for U.S. options.[1] - **Other PAPs**: NeedyMeds, RxAssist for HCV listings. - **Clinical Trials**: Search ClinicalTrials.gov for genotype 3 studies.[7] - **State ADAPs**: AIDS Drug Assistance Programs cover HCV in some states.[4] Consult your healthcare provider for personalized options. ## Disclaimer This guide is for informational purposes only and not medical advice. Daklinza is discontinued; no active BMS PAP exists as of 2026.[1] Eligibility, availability, and terms change—verify with foundations, your doctor, or pharmacist. Word count: 950.

Program information last verified: March 30, 2026